156 related articles for article (PubMed ID: 38511195)
1. Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction.
Sundra T; Kelty E; Rossi G; Rendle D
Front Vet Sci; 2024; 11():1332337. PubMed ID: 38511195
[TBL] [Abstract][Full Text] [Related]
2. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
3. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
Donaldson MT; LaMonte BH; Morresey P; Smith G; Beech J
J Vet Intern Med; 2002; 16(6):742-6. PubMed ID: 12465775
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
5. Effect of dietary carbohydrates and time of year on ACTH and cortisol concentrations in adult and aged horses.
Jacob SI; Geor RJ; Weber PSD; Harris PA; McCue ME
Domest Anim Endocrinol; 2018 Apr; 63():15-22. PubMed ID: 29195115
[TBL] [Abstract][Full Text] [Related]
6. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
Rendle DI; Duz M; Beech J; Parkin T; Durham AE
J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
[TBL] [Abstract][Full Text] [Related]
7. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
8. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
McFarlane D; Banse H; Knych HK; Maxwell LK
J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
[TBL] [Abstract][Full Text] [Related]
10. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
[TBL] [Abstract][Full Text] [Related]
11. Influence of feeding status, time of the day, and season on baseline adrenocorticotropic hormone and the response to thyrotropin releasing hormone-stimulation test in healthy horses.
Diez de Castro E; Lopez I; Cortes B; Pineda C; Garfia B; Aguilera-Tejero E
Domest Anim Endocrinol; 2014 Jul; 48():77-83. PubMed ID: 24906932
[TBL] [Abstract][Full Text] [Related]
12. Plasma Amino Acids in Horses Suffering from Pituitary Pars Intermedia Dysfunction.
Stoeckle SD; Timmermann D; Merle R; Gehlen H
Animals (Basel); 2022 Nov; 12(23):. PubMed ID: 36496836
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.
Tatum RC; McGowan CM; Ireland JL
Vet J; 2020 Dec; 266():105562. PubMed ID: 33323174
[TBL] [Abstract][Full Text] [Related]
14. Initial analytic quality assessment and method comparison of an immunoassay for adrenocorticotropic hormone measurement in equine samples.
Irvine KL; Burt K; Hill AJ; Shaw S; Papasouliotis K
Vet Clin Pathol; 2016 Mar; 45(1):154-63. PubMed ID: 26756538
[TBL] [Abstract][Full Text] [Related]
15. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
Copas VE; Durham AE
Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
[TBL] [Abstract][Full Text] [Related]
16. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.
Miller MA; Pardo ID; Jackson LP; Moore GE; Sojka JE
Vet Pathol; 2008 Jan; 45(1):26-38. PubMed ID: 18192571
[TBL] [Abstract][Full Text] [Related]
17. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
[TBL] [Abstract][Full Text] [Related]
18. Management of pituitary pars intermedia dysfunction in practice: A clinical audit.
Steel NL; Ireland JL; McGowan CM
Vet J; 2022 Nov; 289():105899. PubMed ID: 36162625
[TBL] [Abstract][Full Text] [Related]
19. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Gehlen H; Fisch J; Merle R; Trachsel DS
J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunofluorescence and chemiluminescence assays for measuring ACTH in equine plasma.
McGilvray TA; Knowles EJ; Harris PA; Menzies-Gow NJ
Equine Vet J; 2020 Sep; 52(5):709-714. PubMed ID: 31955443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
